= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Schwamborn

MSACL 2018 EU Abstract

Topic: Tissue Imaging

Podium Presentation in the Ether on Thursday at 9:00 (Chair: Raf Van de Plas)

Next Generation Sequencing After MALDI MSI – A Feasibility Study

Kristina Schwamborn (Presenter)
Institute of Pathology, TU Munich

Authors: Kristina Schwamborn, Christine Bollwein, Anne Jacob, Wilko Weichert, Nicole Pfarr
Institute of Pathology, TU Munich, Munich, Germany


Limited amount of sample material is an inherent problem in early cancer diagnostics. Thus, developing strategies to enable multiple test to be performed on the same tissue section are needed. Combining MALDI MSI and next generation sequencing using only a single tissue section is feasible and could be of value in cases of limited sample material.

Financial Disclosure

Board MemberyesMSD
ExpensesyesRoche, MSD
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: